Luana Calabrò

6.9k total citations · 3 hit papers
111 papers, 4.4k citations indexed

About

Luana Calabrò is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Luana Calabrò has authored 111 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 29 papers in Immunology. Recurrent topics in Luana Calabrò's work include Cancer Immunotherapy and Biomarkers (59 papers), Occupational and environmental lung diseases (31 papers) and Immunotherapy and Immune Responses (22 papers). Luana Calabrò is often cited by papers focused on Cancer Immunotherapy and Biomarkers (59 papers), Occupational and environmental lung diseases (31 papers) and Immunotherapy and Immune Responses (22 papers). Luana Calabrò collaborates with scholars based in Italy, United States and France. Luana Calabrò's co-authors include Michele Maio, Maresa Altomonte, Anna Maria Di Giacomo, Riccardo Danielli, Ester Fonsatti, Diana Giannarelli, Ornella Cutaia, Giovanni Amato, Aldo Morra and Alessia Covre and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Luana Calabrò

108 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients

2009 776 citations Luana Calabrò, Michele Maio et al. profile →
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

2018 336 citations Fabrice Barlési, Johan Vansteenkiste et al. profile →
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

2017 304 citations Michele Maio, Luana Calabrò et al. profile →

Peers

Luana Calabrò

ONCOL

PRM

IMMUN

Thomas Olencki United States

Brenda J. Weigel United States

Maresa Altomonte Italy

Ari M. Vanderwalde United States

Abraham Chachoua United States

Roxana Dronca United States

Leah Haworth United States

Jens Atzpodien Germany

Dimitriοs Mavroudis Greece

Elizabeth I. Buchbinder United States

Thomas Olencki United States

Luana Calabrò

2.0k ×0.9

ONCOL

1.8k ×1.2

PRM

1.6k ×1.1

886 ×0.9

IMMUN

797 ×1.3

Citations per year, relative to Luana Calabrò Luana Calabrò (= 1×) peers Thomas Olencki

Countries citing papers authored by Luana Calabrò

Since Specialization

Citations

This map shows the geographic impact of Luana Calabrò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luana Calabrò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luana Calabrò more than expected).

Fields of papers citing papers by Luana Calabrò

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luana Calabrò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luana Calabrò. The network helps show where Luana Calabrò may publish in the future.

Co-authorship network of co-authors of Luana Calabrò

This figure shows the co-authorship network connecting the top 25 collaborators of Luana Calabrò. A scholar is included among the top collaborators of Luana Calabrò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luana Calabrò. Luana Calabrò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caruso, Francesca Pia, Teresa Noviello, Roberta Mortarini, et al.. (2025). DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy. Journal of Experimental & Clinical Cancer Research. 44(1). 58–58. 1 indexed citations

Magri, Chiara, Aldo Carnevale, Antonella Ciancetta, et al.. (2024). Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report. International Journal of Molecular Sciences. 25(14). 7508–7508.

Camerini, Andrea, Francesca Mazzoni, Vieri Scotti, et al.. (2024). Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Medicine. 13(13). 3642–3642. 3 indexed citations

Sanz, Juana María, Alessio Schirone, Antonio Frassoldati, et al.. (2024). miRNAs profile as a signature for cardiovascular disease in long-term breast cancer female survivors: a pilot study. European Heart Journal. 45(Supplement_1).

Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2023). 1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Annals of Oncology. 34. S653–S654. 2 indexed citations

Tonet, Elisabetta, Matteo Serenelli, Gabriele Guardigli, et al.. (2023). Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. Journal of Clinical Medicine. 12(24). 7737–7737. 25 indexed citations

Bronte, Giuseppe, et al.. (2023). Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?. International Journal of Molecular Sciences. 24(16). 12622–12622. 4 indexed citations

Bravaccini, Sara, Roberta Maltoni, Claudio Cerchione, et al.. (2022). T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. International Journal of Molecular Sciences. 23(15). 8590–8590. 22 indexed citations

Granato, Anna Maria, Emanuela Scarpi, Laura Ridolfi, et al.. (2022). Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center. Vaccines. 10(7). 999–999. 5 indexed citations

10.

Giacomo, Anna Maria Di, Vanna Chiarion‐Sileni, Michele Del Vecchio, et al.. (2021). Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research. 27(17). 4737–4745. 41 indexed citations

11.

Yap, Timothy A., Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.. (2021). Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. The Lancet Respiratory Medicine. 9(6). 613–621. 55 indexed citations

12.

Park, Keunchil, Mustafa Özgüroğlu, Johan Vansteenkiste, et al.. (2021). Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Journal of Thoracic Oncology. 16(8). 1369–1378. 40 indexed citations

13.

Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2020). 1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial. Annals of Oncology. 31. S734–S734. 3 indexed citations

14.

Giacomo, Anna Maria Di, Monica Valente, Alfonso Cerase, et al.. (2019). Immunotherapy of brain metastases: breaking a “dogma”. Journal of Experimental & Clinical Cancer Research. 38(1). 419–419. 69 indexed citations

15.

Maccalli, Cristina, Diana Giannarelli, Ornella Cutaia, et al.. (2017). Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. OncoImmunology. 6(7). e1323618–e1323618. 46 indexed citations

16.

Migliorino, M.R., Alain Gelibter, Francesco Grossi, et al.. (2017). Use of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP). Annals of Oncology. 28. v471–v471. 6 indexed citations

17.

Calabrò, Luana & Michele Maio. (2014). Immune checkpoint blockade in malignant mesothelioma. OncoImmunology. 3(2). e27482–e27482. 13 indexed citations

18.

Giacomo, Anna Maria Di, Riccardo Danielli, Luana Calabrò, et al.. (2010). Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunology Immunotherapy. 60(4). 467–477. 71 indexed citations

19.

Palange, Paolo, Ugo Testa, Alice Huertas, et al.. (2006). Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. European Respiratory Journal. 27(3). 529–541. 148 indexed citations

20.

Musolino, Caterina, et al.. (2002). Soluble angiogenic factors: Implications for chronic myeloproliferative disorders. American Journal of Hematology. 69(3). 159–163. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact